title: Healing potential of a Streptomyces sp. secondary metabolite, SEM-1-111, on experimental full-thickness excision cutaneous wounds in Wistar rats.
abstract: BACKGROUND
  The potent biomedical properties of Streptomyces secondary metabolites make them a possible source of promising new targets to use as wound-healing-promoting agents.
  
  
  OBJECTIVE
  To investigate the properties of a Streptomyces sp. secondary metabolite, the SEM-1-111 fraction, in the healing full-thickness cutaneous wounds.
  
  
  METHODS
  In this experiment, creams were prepared using a Eucerin ointment base with 5%, 10% or 15% SEM-1-111 added. Circular excision wounds were surgically created on the back of Wistar rats, and the creams were applied daily to the wound area. The negative control group was treated with the vehicle, and the positive control group with a commercial phenytoin 1% cream. We analysed planimetric and histological parameters, and the expression of procollagen-I mRNA.
  
  
  RESULTS
  SEM-1-111 substantially influenced wound healing. The cream containing the highest dose of metabolite (15%) significantly decreased wound size during the study, and histological evaluation showed beneficial effects of this concentration in the wound-healing process. Procollagen-I mRNA levels were significantly increased in both the 15% SEM-1-111 group and the phenytoin group compared with the vehicle control on postoperative day 7.
  
  
  CONCLUSIONS
  Regular topical application of the Streptomyces sp. secondary metabolite SEM-1-111 fraction at a concentration of 15% accelerates the wound-healing process.
authors: Department of Molecular Cell Biology, North-west Branch, Razi Vaccine and Serum Research Institute, Marand, Iran. saeed.sadigetegad@gmail.com
authors: S
authors: S
authors: Sadigh-Eteghad
authors: A
authors: A
authors: Dehnad
authors: J
authors: J
authors: Mahmodi
authors: H
authors: H
authors: Hoseyni
authors: I
authors: I
authors: Khalili
authors: N
authors: N
authors: Razmaray
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D009824:Ointments; D051381:Rats; D017208:Rats, Wistar; D013302:Streptomyces / Q000378:metabolism* / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D009824:Ointments